高盛发表报告，指出关于BTK抑制剂(BTKi)领导地位的争论，随着在百悦泽获得美国市场冠军下逐渐平息，投资者焦点正转向BTK抑制剂尚未满足的需求，例如更深且持久的疗效。这可通过添加基于BCL2抑制剂的治疗方案和BTK降解剂有效解决。
该行认为，百济神州在慢性淋巴细胞白血病(CLL)领域的领导地位有望进一步巩固，其BTK/BCL2产品组合，包括BCL2抑制剂具颠覆一线CLL治疗模式的巨大潜力，以及BTK降解剂初步反应数据令人鼓舞，且耐受性良好。基于相关乐观看法，对百济神州(06160.HK) (ONC.US) 美国预托证券(ADR)及A股(688235.SH) 目标价上调至352.98美元及295.09元人民币，投资评级“买入”。
高盛预测，该药物组合2035年经风险调整的销售额为88亿美元，高于之前估算的72亿美元。(fc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-09 16:25。) (A股报价延迟最少十五分钟。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.